HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

Journal of Thoracic Oncology

Volumn 12, Issue 3, 2017, Pages 446-457

  Ou, Sai Hong Ignatius ^a   Schrock, Alexa B ^b   Bocharov, Eduard V ^c   Klempner, Samuel J ^d   Haddad, Carolina Kawamura ^e   Steinecker, Gary ^f   Johnson, Melissa ^g   Gitlitz, Barbara J ^h   Chung, Jon ^b   Campregher, Paulo V ^b,i   Ross, Jeffrey S ^b,j   Stephens, Philip J ^b   Miller, Vincent A ^b   Suh, James H ^b   Ali, Siraj M ^b   Velcheti, Vamsidhar ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FOUNDATION MEDICINE   (United States)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^d Angeles Clinic and Research Institute   (United States)

^e HOSPITAL SÃO JOSÉ   (Brazil)

^f Affiliated Oncologists   (United States)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^j ALBANY MEDICAL COLLEGE   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

Actionable driver mutation; Afatinib; HER2 G660; HER2 V659; NSCLC; Transmembrane mutation

Indexed keywords

AFATINIB; ARGININE; ASPARTIC ACID; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTAMIC ACID; MEMBRANE PROTEIN; TRASTUZUMAB; VINORELBINE TARTRATE; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; RADIOSENSITIZING AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALK GENE; AMINO TERMINAL SEQUENCE; ARTICLE; ASIAN; BRONCHOSCOPY; CARBOXY TERMINAL SEQUENCE; CLINICAL DECISION MAKING; CLINICAL FEATURE; COMPREHENSIVE GENOMIC PROFILING; CONFORMATION; CONTROLLED STUDY; DIMERIZATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; EGFR GENE; FACIAL RASH; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENOMICS; HER2 ONCOGENE; HETERODIMERIZATION; HOMODIMERIZATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PARONYCHIA; PROSPECTIVE STUDY; PROTEIN DOMAIN; RASH; STRUCTURE ANALYSIS; THORAX PAIN; TMD ONCOGENE; TREATMENT DURATION; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY; AMINO ACID SEQUENCE; CANCER STAGING; CHEMISTRY; FOLLOW UP; GENETICS; LUNG TUMOR; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RETROSPECTIVE STUDY; SEQUENCE ALIGNMENT;

ADULT; AGED; AMINO ACID SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN CONFORMATION; PROTEIN DOMAINS; PROTEIN MULTIMERIZATION; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SEQUENCE ALIGNMENT;

EID: 85015314479     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.11.2224     Document Type: Article

References (27)

1. 1 Roskoski, R., ErbB/HER protein-tyrosine kinases: structures and small molecule inhibitors. Pharmacol Res 87 (2014), 42–59.
2. 2 Kovacs, E., Zorn, J.A., Huang, Y., Barros, T., Kuriyan, J., A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem 84 (2015), 739–764.
3. 3 Bocharov, E.V., Lesovoy, D.M., Pavlov, K.V., Pustovalova, Y.E., Bocharova, O.V., Arseniev, A.S., Alternative packing of EGFR transmembrane domain suggests that protein-lipid interactions underlie signal conduction across membrane. Biochim Biophys Acta 1858 (2016), 1254–1261.
4. 4 Kris, M.G., Johnson, B.E., Berry, L.D., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
5. 5 Kris, M.G., Camidge, D.R., Giaccone, G., et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 26 (2015), 1421–1427.
6. 6 Mazières, J., Barlesi, F., Filleron, T., et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 27 (2016), 281–286.
7. 7 Stephens, P., Hunter, C., Bignell, G., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431 (2004), 525–526.
8. 8 Bargmann, C.I., Hung, M.C., Weinberg, R.A., Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45 (1986), 649–657.
9. 9 Serra, V., Vivancos, A., Puente, X.S., et al. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov 3 (2013), 1238–1244.
10. 10 Yamamoto, H., Higasa, K., Sakaguchi, M., et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst, 106, 2014, djt338.
11. 11 Wang, R., Zhang, Y., Pan, Y., et al. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget 6 (2015), 34300–34308.
12. 12 Frampton, G.M., Fichtenholtz, A., Otto, G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
13. 13 Polyansky, A.A., Volynsky, P.E., Efremov, R.G., Multistate organization of transmembrane helical protein dimers governed by the host membrane. J Am Chem Soc 134 (2012), 14390–14400.
14. 14 PREDDIMER Prediction Tool for an Ensemble of Transmembrane α-Helical Dimer Conformations. Predict a dimer structure. http://model.nmr.ru/preddimer/. Accessed November 7, 2013.
15. 15 Mineev, K.S., Bocharov, E.V., Pustovalova, Y.E., Bocharova, O.V., Chupin, V.V., Arseniev, A.S., Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. J Mol Biol 400 (2010), 231–243.
16. 16 Hess, B., Kutzner, C., van der Spoel, D., Lindahl, E., GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4 (2008), 435–437.
17. 17 Koradi, R., Billeter, M., Wüthrich, K., MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 14 (1996), 51–55 29–32.
18. 18 Barlesi, F., Mazieres, J., Merlio, J.-P., et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387 (2016), 1415–1426.
19. 19 Tomizawa, K., Suda, K., Onozato, R., et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 74 (2011), 139–144.
20. 20 Bocharov, E.V., Mineev, K.S., Volynsky, P.E., et al. Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state. J Biol Chem 283 (2008), 6950–6956.
21. 21 CBio Portal for Cancer Genomics. Visualize, analyze, discover. www.cbioportal.org. Accessed May 2, 2016.
22. 22 Suzawa, K., Toyooka, S., Sakaguchi, M., et al. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. Cancer Sci 107 (2016), 45–52.
23. 23 Endres, N.F., Das, R., Smith, A.W., et al. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152 (2013), 543–556.
24. 24 Bocharov, E.V., Lesovoy, D.M., Goncharuk, S.A., Goncharuk, M.V., Hristova, K., Arseniev, A.S., Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies. Structure 21 (2013), 2087–2093.
25. 25 Vidal, G.A., Clark, D.E., Marrero, L., Jones, F.E., A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities. Oncogene 26 (2007), 462–466.
26. 26 Gallant, J.N., Sheehan, J.H., Shaver, T.M., et al. EGFR kinase domain duplication (EGFR-KDD)i a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov 5 (2015), 1155–1163.
27. 27 Konduri, K., Gallant, J.N., Chae, Y.K., et al. EGFR fusions as novel therapeutic targets in lung cancer. Cancer Discov 6 (April 21, 2016), 601–611.